Novartis AG/€NOVN

05:30
08:40
11:45
14:55
18:00
1D1W1MYTD1Y5YMAX

About Novartis AG

Novartis AG is a global healthcare company based in Switzerland, specializing in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products. The company's core business is centered around patented prescription medicines in areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis operates in over 150 countries worldwide. Its strategic positioning is reinforced by significant investments in research and development, supporting a robust pipeline of innovative therapies. The company is headquartered in Basel, Switzerland, and emphasizes its competitive strength through advanced research capabilities and a diverse product portfolio.

Ticker

€NOVN
Sector

Primary listing

XGAT

Employees

75,883

Headquarters

Basel, Switzerland

Novartis AG Metrics

BasicAdvanced
€218B
19.46
€5.83
0.56
€3.65
3.22%

Bulls say / Bears say

Novartis raised its full-year 2025 operating income guidance to low double-digit growth after adjusted Q1 net income jumped 22% to $4.48 billion, well above analyst projections (Reuters)
Revenue from breast cancer drug Kisqali surged 52% to $956 million and cholesterol therapy Leqvio rose 70% to $257 million in Q1, underscoring strong commercial momentum for key growth drivers (Reuters)
The FDA approved Rhapsido (remibrutinib) for chronic spontaneous urticaria on September 30, introducing a high-priced oral BTK inhibitor that delivered complete symptom relief in one-third of trial patients by week 12 (Reuters)
A U.S. federal judge denied Novartis’ request for a preliminary injunction to block MSN Pharmaceuticals from marketing a generic version of Entresto, ending its market exclusivity on July 16, 2025 and threatening to erode revenues from the $7.8 billion drug (Reuters)
Novartis’ Cosentyx failed to achieve sustained remission in a late-stage Phase III trial for giant cell arteritis, representing a setback in its immunology pipeline and raising questions about growth prospects in that therapeutic area (Reuters)
The proposed 100% U.S. tariff on imported patented pharmaceuticals poses policy risk and cost uncertainty for Novartis despite its planned $23 billion U.S. investment, as details of potential exemptions remain unclear (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €NOVN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs